Stavroula Sofou

Prof. Dr. Stavroula Sofou

Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
APAprameya Prasad
Aprameya Prasad
RNRajiv Nair
Rajiv Nair
OBOmkar Bhatavdekar
Omkar Bhatavdekar
AHAlaina Howe
Alaina Howe
DSDominick Salerno
Dominick Salerno
SSStavroula Sofou
Stavroula Sofou

11 December 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SSSally Stras
Sally Stras
AHAlaina Howe
Alaina Howe
APAprameya Prasad
Aprameya Prasad
DSDominick Salerno
Dominick Salerno
OBOmkar Bhatavdekar
Omkar Bhatavdekar
SSStavroula Sofou
Stavroula Sofou

18 November 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AHAlaina Howe
Alaina Howe
OBOmkar Bhatavdekar
Omkar Bhatavdekar
DSDominick Salerno
Dominick Salerno
AJAnders Josefsson
Anders Josefsson
JPJesus Pacheco-Torres
Jesus Pacheco-Torres
SSStavroula Sofou
Stavroula Sofou
Alpha-particle radiotherapy has already been shown to be impervious to most resistance mechanisms. However, in established (i.e. large, vascularized) soft-tissue lesions, the diffusion-limited penetration depths of radiolabeled antibodies and/or nanocarriers (up to 50-80µm) combined with the short range of α-particles (4-5 cell diameters) may result in only partial tumor irradiation potentially limiting treatment efficacy. To address this challenge, we combined carriers with complementary intratumoral microdistributions of the delivered α-particles. We use the α-particle generator Actinium-225 (225Ac), and we combine (1) a tumor-responsive liposome that upon tumor uptake releases in the interstitium a highly-diffusing form of its radioactive payload (225Ac-DOTA), which may penetrate the deeper parts of tumors where antibodies do not reach, with (2) a separately administered, less-penetrating radiolabeled-antibody irradiating the tumor perivascular regions from where liposome contents clear too fast. Methods: On a murine model with orthotopic HER2-positive BT474 breast cancer xenografts, the biodistributions of each carrier were evaluated, and the control of tumor growth was monitored after administration of the same total radioactivity of 225Ac delivered (1) by the 225Ac-DOTA-encapsulating liposomes, (2) by the 225Ac-DOTA-SCN-labeled-trastuzumab, and (3) by both carriers at equally split radioactivities. Results: Tumor growth inhibition was significantly more pronounced when the same total injected radioactivity was divided between the two separate carriers, as compared to the growth delay by the same total injected radioactivity when delivered by either of the carriers alone. The combined carriers enabled more uniform intratumoral microdistributions of α-particles, at a tumor delivered dose that was lower than the dose delivered by the antibody alone. Significance: This strategy demonstrates that more uniform microdistributions of the delivered α-particles within established solid tumors improve efficacy even at lower tumor delivered doses. Augmentation of antibody-targeted α-particle therapies with tumor-responsive liposomes may address partial tumor irradiation improving therapeutic effects.

8 November 2021 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
DSDominick Salerno
Dominick Salerno
AHAlaina Howe
Alaina Howe
OBOmkar Bhatavdekar
Omkar Bhatavdekar
AJAnders Josefsson
Anders Josefsson
JPJesus Pacheco‐Torres
Jesus Pacheco‐Torres
SSStavroula Sofou
Stavroula Sofou
Partial and/or heterogeneous irradiation of established (i.e., large, vascularized) tumors by α‐particles that exhibit only a 4–5 cell‐diameter range in tissue, limits the therapeutic effect, since regions not being hit by the high energy α‐particles are likely not to be killed. This study aims to mechanistically understand a delivery strategy to uniformly distribute α‐particles within established solid tumors by simultaneously delivering the same α‐particle emitter by two diverse carriers, each killing a different region of the tumor: (1) the cancer‐agnostic, but also tumor‐responsive, liposomes engineered to best irradiate tumor regions far from the vasculature, and (2) a separately administered, antibody, targeting any cancer‐cell's surface marker, to best irradiate the tumor perivascular regions. We demonstrate that on a prostate specific membrane antigen (PSMA)‐expressing prostate cancer xenograft mouse model, for the same total injected radioactivity of the α‐particle emitter Actinium‐225, any radioactivity split ratio between the two carriers resulted in better tumor growth inhibition compared to the tumor inhibition when the total radioactivity was delivered by any of the two carriers alone. This finding was due to more uniform tumor irradiation for the same total injected radioactivity. The killing efficacy was improved even though the tumor‐absorbed dose delivered by the combined carriers was lower than the tumor‐absorbed dose delivered by the antibody alone. Studies on spheroids with different receptor‐expression, used as surrogates of the tumors' avascular regions, demonstrated that our delivery strategy is valid even for as low as 1+ (ImmunoHistoChemistry score) PSMA‐levels. The findings presented herein may hold clinical promise for those established tumors not being effectively eradicated by current α‐particle radiotherapies.

26 May 2021 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
AHAlaina Howe
Alaina Howe
SSStavroula Sofou
Stavroula Sofou

20 April 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
RNRajiv Ranjit Nair
Rajiv Ranjit Nair
APAprameya Prasad
Aprameya Prasad
OBOmkar Bhatavdekar
Omkar Bhatavdekar
ASAira Sarkar
Aira Sarkar
KGKathleen L. Gabrielson
Kathleen L. Gabrielson
SSStavroula Sofou
Stavroula Sofou